Pharmacogenetics of Alcohol: Treatment Implications

NACompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

July 31, 2011

Conditions
Alcohol Related DisordersAlcoholismAlcohol Abuse
Interventions
DRUG

dutasteride + ethanol

4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes

DRUG

placebo medication + ethanol

placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes

DRUG

dutasteride + placebo alcohol

4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes

DRUG

placebo medication + placebo alcohol

placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes

Trial Locations (1)

06030

University of Connecticut Health Center, Farmington

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

UConn Health

OTHER

NCT00734656 - Pharmacogenetics of Alcohol: Treatment Implications | Biotech Hunter | Biotech Hunter